Adicet Bio Gestione

Gestione criteri di controllo 2/4

Adicet Bio Il CEO è Chen Schor, nominato in Sep2020, e ha un mandato di 4.17 anni. la retribuzione annua totale è $ 5.97M, composta da 10.1% di stipendio e 89.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di $ 121.95K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.1 anni e 3.5 anni.

Informazioni chiave

Chen Schor

Amministratore delegato

US$6.0m

Compenso totale

Percentuale dello stipendio del CEO	10.1%
Mandato del CEO	4.2yrs
Proprietà del CEO	0.2%
Durata media del management	4.1yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chen Schor rispetto agli utili di Adicet Bio?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$118m
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

Compensazione vs Mercato: La retribuzione totale di Chen ($USD 5.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 354.57K ).

Compensazione vs guadagni: La retribuzione di Chen è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Chen Schor (52 yo)

4.2yrs

Mandato

US$5,973,807

Compensazione

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Chen Schor	CEO, President & Director	4.2yrs	US$5.97m	0.16% $ 121.9k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 774.4k
Brian Harvey	Chief Financial Officer	4.2yrs	US$2.13m	0.068% $ 50.7k
Donald Healey	Chief Technology Officer	4.1yrs	US$2.09m	0.043% $ 31.8k
Blake Aftab	Senior VP & Chief Scientific Officer	3.6yrs	US$2.48m	0.031% $ 23.0k
Amy Locke	Chief Human Resource Officer	2.8yrs	Nessun dato	Nessun dato
Francesco Galimi	Chief Medical Officer & Senior VP	4.2yrs	US$1.99m	0.092% $ 68.3k
Nancy Boman	Senior VP & Chief Regulatory Officer	2yrs	Nessun dato	Nessun dato

4.1yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di 0HX7 è considerato esperto (durata media dell'incarico 4.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Chen Schor	CEO, President & Director	4.2yrs	US$5.97m	0.16% $ 121.9k
Aya Jakobovits	Founder & Independent Director	4.2yrs	US$240.29k	1.04% $ 774.4k
Carl Gordon	Independent Chairman	4.2yrs	US$275.29k	0.0072% $ 5.3k
Steve Dubin	Independent Director	4.2yrs	US$254.29k	0.013% $ 9.9k
Andrew Sinclair	Independent Director	3.7yrs	US$255.29k	0.0072% $ 5.3k
Jeffrey Chodakewitz	Independent Director	4.2yrs	US$240.29k	0.0072% $ 5.3k
Marco Davila	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 92.8k
Michael Kalos	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Saul Priceman	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Constantine Mitsiades	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Alice Bertaina	Member of Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0HX7 sono considerati esperti (durata media dell'incarico 3.5 anni).

Adicet Bio Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

New minor risk - Market cap size

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media